secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001140361-24-000542
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

atai Life Sciences invests $50M in Beckley Psytech for 35.5% stake, adding two clinical-stage psychedelic programs
--------------------------------------------------------------------------------

- Total investment $50M: $40M primary issuance + $10M secondary share purchase; atai to own ~35.5% of Beckley Psytech.
- Acquires BPL-003 (intranasal 5-MeO-DMT) for Treatment Resistant Depression and Alcohol Use Disorder, and ELE-101 (IV psilocin) for MDD.
- Multiple clinical readouts expected within 12 months, including Phase 2b BPL-003 TRD data in 2H24.
- atai receives 1:1 warrant coverage at 30% premium on primary, 3 of 9 board seats, and right of first refusal/negotiation.
- Beckley Psytech remains independent; transaction closed Jan 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/0001140361-24-000542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/ef20017595_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-000542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer